<DOC>
	<DOCNO>NCT01126684</DOCNO>
	<brief_summary>To evaluate possible effect atorvastatin ambulatory blood pressure , urinary albumin excretion , insulin resistance arterial stiffness hypertensive patient , beyond lipid profile . Glycemic parameter , `` novel '' cardiovascular risk factor safety parameter also evaluate .</brief_summary>
	<brief_title>Effects Atorvastatin Blood Pressure Urinary Albumin Excretion</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>LDLC &gt; 130 &gt; 160 mg/dL ( depend total risk accord recent recommendations25 ) . previous hypolipidemic medication ability provide Informed Consent . pregnancy lactation myocardial infarction unstable angina within past 6 month heart failure NYHA class IIIIV renal disease ( SCr &gt; 3 mg/dL proteinuria &gt; 3g/d ) liver disease history malignancy history drug alcohol abuse treatment corticosteroid condition poor prognosis inability provide Informed Consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>essential hypertension</keyword>
</DOC>